Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from BIIB

Biogen Stock Outlook: Is Wall Street Bullish or Bearish?

Biogen has lagged well behind the broader market over the past year, yet analysts maintain a fairly optimistic outlook on its future performance.

Barchart

Biogen Stock Is Mutating Into a Value Play

Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X

MarketBeat

Biogen's Quarterly Earnings Preview: What You Need to Know

Biogen is scheduled to release its fourth-quarter earnings next month, and analysts are forecasting a double-digit increase in its bottom line.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biotech Stocks Innovating the Future of Medicine

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing advancements like AI. Therefore, fundamentally sound biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Gilead Sciences (GILD), which are at the forefront of innovation, could be ideal portfolio additions. Read more.

StockNews.com

Biogen Stock: Is BIIB Underperforming the Healthcare Sector?

Biogen has recently lagged behind the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on the stock's long-term growth potential.

Barchart

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

StockNews.com

Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?

Biogen has significantly underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stocks Predicted to Surge on Medical Innovation

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, investors might consider adding fundamentally strong biotech stocks like Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Gilead Sciences (GILD) to their portfolio for an impactful investment. Continue reading….

StockNews.com

Biogen's Q3 2024 Earnings: What to Expect

Biogen will release its third-quarter earnings this month, and analysts anticipate a double-digit profit dip.

Barchart

3 Biotech Stocks Set to Revolutionize Medicine

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…

StockNews.com

3 Biotech Stocks With Huge Upside Based on Analyst Price Targets

The biotech sector’s long-term growth is fueled by strong government support, increasing funding and M&A activities, and rapid AI adoption. Therefore, quality biotech stocks Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), and Biogen (BIIB) with major upside could be ideal additions to your portfolio. Keep reading.

StockNews.com

3 Biotech Stocks Wall Street Predicts Will Skyrocket

Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To capitalize on this opportunity, consider investing in fundamentally sound biotech stocks Biogen (BIIB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN), that are poised to skyrocket. Learn more.

StockNews.com

3 Biotech Stocks That Could Deliver Big Gains

The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of new therapeutics, and increased R&D spending on treatments for new and rare diseases. Hence, investors should consider strong biotech stocks such as Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which could deliver big…

StockNews.com

Is Biogen Stock Underperforming the Dow?

Biogen has underperformed the Dow over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Healthcare Stocks With High Analyst Price Targets

Recent innovations, successful trials, and increased research and development spending in the healthcare sector further boost the sector’s appeal today. Given this momentum, investors might consider investing in stocks with high analyst price targets, such as Pfizer (PFE), Biogen (BIIB), and BioMarin Pharmaceutical (BMRN). Read on….

Barchart

Is Wall Street Bullish or Bearish on Biogen Stock?

Despite Biogen’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately bullish about the stock’s prospects.

Barchart

Biogen Earnings Preview: What to Expect

Biogen is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

Barchart

Is Biogen Stock Underperforming the Nasdaq?

Biogen underperforms the Nasdaq Composite, and analysts remain cautiously optimistic about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

5 Biotech Stocks With 26% Upside Potential or More

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

StockNews.com

Moderna (MRNA) and Biogen (BIIB) - Are There Upsides Left in These Biotech Stocks?

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience. So, let’s analyze the upside potential of popular biotech stocks Biogen (BIIB) and Moderna (MRNA).

StockNews.com

Biogen (BIIB): Earnings Alert - Key Insights

Because of its strategic focus on research and therapy improvements for long-term growth, Biogen (BIIB) could come under heat for the mixed outcomes of its recent acquisitions. As stakeholders anticipate the forthcoming earnings release, let's seek insights into the company's future trajectory and implications for BIIB shares. Read on….

StockNews.com

Buy, Hold, or Sell? Analyzing 3 Biotech Stocks Investors Are Watching

Amid the use of advanced technologies, personalized medicines, demand for quality treatments and therapies, and an aging population, the biotech industry appears to be on a steady path for expansion. Given this backdrop, let’s analyze the fundamentals of Biogen (BIIB), BioNTech (BNTX), and Kura (KURA) to determine which of these…

StockNews.com

GILD, BIIB, and KRTX: Biotech Buy, Hold, or Sell?

Rising healthcare needs, significant investments in R&D, robust drug pipeline, and use of advanced technology are some factors driving the biotech industry’s growth. Amid this favorable backdrop, let’s evaluate Gilead (GILD), Biogen (BIIB) and Karuna Therapeutics (KRTX) to determine the best investment action. Read more.

StockNews.com

Biogen (BIIB) Earnings Spotlight: Is the Biotech Stock a Buy or Sell?

Biotech major Biogen (BIIB) will report its third-quarter results on November 8. Its EPS and revenue are expected to decline year-over-year. However, the FDA approvals for new drugs received by the company this year will likely support its long-term growth. Let’s discuss the potential road ahead for the stock….

StockNews.com

3 Biotech Gainers to Consider

Robust demand, technological advancements, government and private investment, are fueling the biotech industry’s expansion and driving game-changing therapies and product development. With the industry anticipated to thrive, fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and United Therapeutics (UTHR) look poised for substantial gains. Keep reading.

1 2 3 4 5

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.